Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD6-H5254 | Human | Human CD46 Protein, Fc Tag (MALS verified) |  |
|
|
| CD6-H5226 | Human | Human CD46 Protein, His Tag (MALS verified) |  |
|
|
Immobilized Human CD46, His Tag (Cat. No. CD6-H5226) at 1 μg/mL (100 μL/well) can bind FG-3246 (FOR46), Human IgG1 kappa with a linear range of 0.3-2 ng/mL (QC tested).
The purity of Human CD46 Protein, Fc Tag (Cat. No. CD6-H5254) is more than 90% and the molecular weight of this protein is around 85-105 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-CD46 antibody drug conjugate (Fortis Therapeutics) | FOR-46; FG-3246 | Phase 2 Clinical | University Of California San Diego | Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Prostatic Neoplasms | Details |
| Enadenotucirev | ColoAd-1; Oncolytic Ad11/Ad3 | Phase 1 Clinical | Akamis Bio Ltd | Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AugmAb | BRM-132 | Phase 1 Clinical | Neoplasms; Lymphoma, Non-Hodgkin | Details | |
| YS-5 | YS-5 | Phase 1 Clinical | Fortis Therapeutics Inc, United States Department Of Defense | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| FG-3180 | 89Zr-DFO-YS-5; 89Zr-DFO-YS5 | Phase 1 Clinical | Fortis Therapeutics Inc | Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
